Cambridge Cognition announces mental health assessment software
AIM-listed digital neuroscience company Cambridge Cognition has been working on a new software product to assess mental health and well-being at work.
Cambridge Cognition Holdings
37.00p
16:55 27/12/24
FTSE AIM All-Share
715.19
17:00 27/12/24
Health Care Equipment & Services
10,692.12
16:35 27/12/24
CANTAB BrainHealth is a digital health product designed for occupational health professionals aimed at measuring and monitoring mental well-being and cognitive performance in the workplace
Cambridge Cognition expects to work closely with channel partners, initially in the US and the UK, to commercialise its proprietary cognitive assessment technology.
The firm claims its new product can accurately measure cognition and mood objectively, identifying signs of an underlying brain health condition early.
Dr Jenny Brockis, an independent brain health and workplace performance consultant said, "The objective mood and cognition assessments are sensitive to the potential presence of an underlying mental health condition, facilitating early intervention before productivity and performance are impacted."
Dr Steven Powell, Cambridge Cognition's chief executive, added, "We are delighted to announce this important digital health product, building on the success of our gold standard technologies used in over one million clinical trial assessments. CANTAB BrainHealth software will be licensed globally to occupational health providers and channel partners, offering an urgent solution for employers and enabling their employees to thrive."
As of 1650 BST, Cambridge Cognition shares had dipped 0.59% to 168p.